Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Carcinoma, Non-Small-Cell Lung 12Breast Neoplasms 11Prostatic Neoplasms 10Glioblastoma 10Oropharyngeal Neoplasms 7Rectal Neoplasms 6Neoplasms 6Lung Neoplasms 6Astrocytoma 6Squamous Cell Carcinoma of Head and Neck 5Urinary Bladder Neoplasms 4Burkitt Lymphoma 4Adenocarcinoma of Lung 4Pancreatic Neoplasms 3Nasopharyngeal Carcinoma 3Mouth Neoplasms 3Lymphoma, Follicular 3Hodgkin Disease 3Gliosarcoma 3Glioma 3Esophageal Neoplasms 3Carcinoma, Squamous Cell 3Carcinoma 3Triple Negative Breast Neoplasms 2Sarcoma 2Rhabdomyosarcoma 2Neoplasm, Residual 2Mesothelioma, Malignant 2Meningeal Carcinomatosis 2Lymphoma, Large B-Cell, Diffuse 2

Interventions

temsirolimus 1Vinorelbine 1Vincristine 1Sirolimus 1Radiotherapy 1Radiation 1Irinotecan 1Dactinomycin 1Cyclophosphamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Rhabdomyosarcoma, Alveolar × Radiotherapy × 30 days × Clear all
NCT02567435 2026-05-27

Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma

National Cancer Institute (NCI)

Phase 3 Active not recruiting
325 enrolled 14 charts
Sarcoma

Rhabdomyosarcoma, Rhabdomyosarcoma, Alveolar, Rhabdomyosarcoma, Embryonal

Data powered by HemOnc (CC BY 4.0) Colophon âš¡